best turn-around thesi
unchang stock cheap buy
report light rev ep maintain guidanc result
prove thesi bear yet still turn-around underway next
 play stock trade pe worst mostli behind
see stabil rev pot multipl expans low
grow pipelin filgotinib pill phase data
ra uc nash phase data low expect
pictur still think repres attract recoveri stock
earn gone last year -- see revs/earn stabil
grow want u-shap recoveri especi pe
reflect bearish pessimist outlook under-own institut ownership
might earli bull camp overal sentiment tape
help still play think better day ahead
reiter buy full detail commentari insid
key issu result hiv miss hcv miss result
ep miss vs con miss environ two
big line-item go motiv broader investor buy hcv miss
key sensit issu admittedli surprisingli due competit mostli
ou beat miss bear keep say hcv
downward spiral stabil yet
posit kite bright spot math convo w/ management suggest
hiv miss viread gener go quickli vs consensu eros
inventori draw greater normal management state us hiv yy script
demand report delta last year
viread gener like inventori hcv miss good
management say big step due new price contract went effect
slower declin bad japan miss
proxi eu guidanc still play kite yescarta strong vs
con kite-app model suggest year vs con
nv got approv today dlbcl expect
pt base pipeline-adjust dcf ep estim
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
pt base view remain
cheap low-expect stori around
earn revenu earn could flat
declin next year
analysi suggest durabl hiv busi along
importantli includ string-of-
pearl type bolt-on continu build mid/lat
stage pipelin improv visibl
upsid scenario price base appli
multipl non-gaap ep estim
dcf base busi pipelin product
upsid target base durabl hiv busi
remain flattish instead declin post
could see multipl expans near-term
stabil and/or growth hep franchis
upsid posit data readout pipelin program
nash hep oncolog
yescarta launch goe better expect
downsid scenario base appli
multipl non-gaap ep estim
yescarta launch could miss analyst estim
viread face new gener particularli eu start
hcv franchis like face price pressur
new effect hcv regimen
gsk could take increas market share hiv base
believ continu
potenti gene therapy/ gene edit space
believ gild hiv franchis could durabl
believ hcv busi increas visibl
becom manag volum stabil
get deeper sever near-
term driver grind higher
gsk gemini studi show dtg doublet good
baricitinib launch first phase filgotinib ra
data
robust yescarta launch
phase nash data
page
pleas see import disclosur inform page report
takeaway confer call
headlin ep perspect bull us
look -- ye market environ particularli reward
stock right miss -- peel back fundament onion
number suggest short-term print realli chang
thesi turn-around stori particularli conserv management reiter
guidanc suggest like track
ye mix result littl bit bull bear reiter think
probabl bounc admit stock first investor like
see miss partli inventori issu hiv spoke compani
believ emphas see -- compani like market
buy stock w/ author open also get season
way histor better think stock bounc dip
fundament standpoint hiv seem fine hcv littl weaker surpris frankli
move baffl downsid speak investor sentiment larg cap
need short-term thesi
bear domin convers basic point hiv miss miss
specif quantifi drawdown hcv miss take
share bottom hcv miss generalist want see
still reiter hcv guidanc whether good thing overhang yee
bull thesi turn-around clear today result -- need prove
confer call compani note
said hiv inventori magnitud chang larger
past miss estimate vs con
also rev viread gener report vs con
ran number w/ management commentari suggest inventori
drawdown key culprit script grew yy despit hiv rev
yy last year simpl math say around
inventori impact view inventori drawdown due gener
viread us hbv use less need older hiv regimen due ramp
biktarvi biktarvi half inventori stock said
launch line w/ expect week revenu percent
come switch regimen one-third genvoya
gsk regimen
said still think hcv rang prior guidanc hcv
miss competit environ stiff ou still reiter gener
impli hcv guidanc slide slide part overal
product revenu acknowledg print
impli probabl low end guidanc view management
emphas big step price got adjust new
contract hit taken modest declin
-- target zone think w/ guidanc
said think trough year grow base
similar said take hiv hcv yescarta
think hcv stabil growth year
kite yescarta beat posit commentari get
specif management said earli day go get detail center
page
pleas see import disclosur inform page report
comfort launch date pleas revenu
rel confid nash pipelin despit easl investor
feedback nash combo mix data see prior note
short studi investor look good
indic need placebo longer mo studi biopsi
differ interpret base reader news phase nash data
consensu mostli free call option
result detail
net product sale y/i came lower consensu
total product sale row
net product sale result reduc patient start competit
hcv busi inventori drawdown hiv non-gaap ep also miss vs
consensu
total hcv sale declin q/q came consensu
us hcv eu hcv sale declin respect
directli attribut increas competit ou market particularli
japan price contract reason big step-down
intern sale
total number patient start appear flatten compar
legaci hcv product harvoni epclusa sovaldi came lower
sequenti vosevi approv us eu juli
gener sale compar
compani note price mostli steadi compani anticip
patient share stabil mid-year
hiv hbv sale y/i consensu mainli
due season inventori drawdown
descovey-contain total hiv sale sale
percent gild total prescript volum hiv contain descovey
genvoya continu well number prescrib hiv regimen
nave pt us number nave number
patient
note viread went gener last quarter result approxim
loss hiv revenu
yescarta sale beat consensu healthi util
compani continu reiter measur launch want ensur
proper usag patient experi yescarta
april compani center certifi anticip
enough centr certifi cover elig patient
follow posit chmp decis april compani expect ema
decis
guidanc reiter
page
pleas see import disclosur inform page report
